Wassilios G Meissner, Philippe Remy, Caroline Giordana, David Maltête, Pascal Derkinderen, Jean-Luc Houéto, Mathieu Anheim, Isabelle Benatru, Thomas Boraud, Christine Brefel-Courbon, Nicolas Carrière, Hélène Catala, Olivier Colin, Jean-Christophe Corvol, Philippe Damier, Estelle Dellapina, David Devos, Sophie Drapier, Margherita Fabbri, Vanessa Ferrier, Alexandra Foubert-Samier, Solène Frismand-Kryloff, Aurore Georget, Christine Germain, Stéphane Grimaldi, Clémence Hardy, Lucie Hopes, Pierre Krystkowiak, Brice Laurens, Romain Lefaucheur, Louise-Laure Mariani, Ana Marques, Claire Marse, Fabienne Ory-Magne, Vincent Rigalleau, Hayet Salhi, Amandine Saubion, Simon R W Stott, Claire Thalamas, Claire Thiriez, Mélissa Tir, Richard K Wyse, Antoine Benard, Olivier Rascol
BACKGROUND: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease. METHODS: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period...
April 4, 2024: New England Journal of Medicine